JAK2 and diffuse large B-cell lymphoma: ABC-DLBCL is characterized by frequent accumulation of MyD88 mutations and constitutively activated NF-κB and JAK2-STAT3 signaling pathways (Davis et al., 2001; Ding et al., 2008; Lam et al., 2008b).